AEON Biopharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 36.63 million compared to USD 52.56 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | +1.92% |
|
+10.35% | -85.28% |
Jul. 09 | AEON Biopharma Plans to Pursue Biosimilar Regulatory Pathway for ABP-450 | MT |
Jul. 09 | AEON Biopharma, Inc. Announces Strategic Reprioritization to Pursue A Biosimilar Pathway for ABP-450 | CI |
![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-85.28% | 40.69M | |
+20.95% | 127B | |
+23.00% | 116B | |
+25.15% | 27.69B | |
-19.75% | 19.62B | |
-16.57% | 16.26B | |
-16.56% | 15.49B | |
+11.19% | 14.81B | |
-46.65% | 14.39B | |
+57.74% | 14.11B |
- Stock Market
- Equities
- AEON Stock
- News AEON Biopharma, Inc.
- AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023